Five Prime Therapeutics Inc. (NASDAQ:FPRX) insider Francis Willard Sarena sold 34,654 shares of the stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $60.38, for a total transaction of $2,092,408.52. Following the transaction, the insider now directly owns 94,731 shares of the company’s stock, valued at approximately $5,719,857.78. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) opened at 58.635 on Tuesday. Five Prime Therapeutics Inc. has a 52-week low of $28.01 and a 52-week high of $60.98. The company has a 50-day moving average of $52.11 and a 200-day moving average of $47.66. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of 6.551 and a beta of 4.48.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by $0.21. Five Prime Therapeutics had a net margin of 64.94% and a return on equity of 59.23%. The firm earned $6.70 million during the quarter, compared to analysts’ expectations of $7.50 million. During the same period in the previous year, the firm posted ($0.93) EPS. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. Equities research analysts anticipate that Five Prime Therapeutics Inc. will post ($2.18) EPS for the current year.

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

TRADEMARK VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of US & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/29/five-prime-therapeutics-inc-fprx-insider-francis-willard-sarena-sells-34654-shares-of-stock.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. purchased a new position in Five Prime Therapeutics during the third quarter worth $30,903,000. Acadian Asset Management LLC boosted its position in Five Prime Therapeutics by 112.1% in the second quarter. Acadian Asset Management LLC now owns 1,094,368 shares of the company’s stock worth $45,250,000 after buying an additional 578,411 shares during the last quarter. FMR LLC boosted its position in Five Prime Therapeutics by 24.1% in the second quarter. FMR LLC now owns 2,817,208 shares of the company’s stock worth $116,492,000 after buying an additional 547,808 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in Five Prime Therapeutics during the second quarter worth $19,498,000. Finally, Vanguard Group Inc. boosted its position in Five Prime Therapeutics by 43.5% in the second quarter. Vanguard Group Inc. now owns 1,472,276 shares of the company’s stock worth $60,877,000 after buying an additional 446,311 shares during the last quarter. 95.40% of the stock is owned by institutional investors.

Several research analysts have commented on the stock. Leerink Swann reissued an “outperform” rating and set a $58.00 price objective (up previously from $45.00) on shares of Five Prime Therapeutics in a report on Monday, August 8th. Jefferies Group set a $60.00 price objective on shares of Five Prime Therapeutics and gave the company a “buy” rating in a report on Friday, August 5th. Citigroup Inc. assumed coverage on shares of Five Prime Therapeutics in a report on Tuesday, October 25th. They set a “buy” rating and a $65.00 price objective for the company. Finally, Credit Suisse Group AG restated a “buy” rating and set a $54.00 target price on shares of Five Prime Therapeutics in a research report on Monday, November 7th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Five Prime Therapeutics presently has an average rating of “Buy” and an average target price of $54.43.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

5 Day Chart for NASDAQ:FPRX

Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.